<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620125</url>
  </required_header>
  <id_info>
    <org_study_id>Lactobacillus reuteri pilot</org_study_id>
    <nct_id>NCT01620125</nct_id>
  </id_info>
  <brief_title>Metabolic Control Before and After Supplementation With Lactobacillus Reuteri DSM 17938 in Type 2 Diabetes Patients</brief_title>
  <official_title>Metabolic Control of Type 2 Diabetes Patients Before and After Dietary Supplementation With the Probiotic Lactobacillus Reuteri DSM 17938 - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent data suggest that the trillions of bacteria in the investigators gastrointestinal
      tracts (gut microbiota) can function as an environmental factor that modulates the amount of
      body fat. Obese individuals have an altered gut microbiota and germ-free mice are resistant
      to developing diet-induced obesity and have lower fasting insulin and glucose and improved
      glucose tolerance. Administration of the probiotic bacterium Lactobacillus strain in
      fermented milk for 12 weeks reduced adiposity and body weight in obese adults, possibly by
      reducing lipid absorption and inflammatory status. However, there are no studies to the
      investigators knowledge that address whether probiotic supplementation improves glucose
      metabolism in type 2 diabetes patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HOMA index</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine improved glucose handling and insulin sensitivity in adult type 2 diabetic patients supplemented with the probiotic L. reuteri DSM 17938 over a 12 week period, we assess insulin sensitivity via the HOMA index (fp-Glucose x fS-Insulin divided by 22.5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in diabetes medication and hypoglycemia events</measure>
    <time_frame>12 weeks</time_frame>
    <description>We monitor changes in diabetes medication and hypoglycemia events. Dosages of medication with oral hypoglycemic agents and number of insulin units per 24 hrs and number of hypoglycemia events will be registered in diaries.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Lactobacillus reuteri</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dietary supplementation with Lactobacillus reuteri DSM 17938</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri DSM 17938</intervention_name>
    <description>Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks</description>
    <arm_group_label>Lactobacillus reuteri</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes with a duration &gt; 6 months

          -  Abdominal obesity

          -  HbA1c 50-80 mmol/mol

          -  Written informed consent

          -  Stated availability throughout the study period

        Exclusion Criteria:

          -  Autoimmune diabetes eg type 1 diabetes

          -  Psychiatric illness or cancer diagnosis

          -  No foreseeable need of treatment with corticosteroids or antibiotics

          -  Inflammatory bowel disease

          -  Administration of antibiotics 4 weeks before inclusion

          -  Administration of probiotics 2 weeks before inclusion

          -  Participation in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per-Anders E jansson, Adj prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Wallenberg Laboratory, Bruna Stråket 16, Sahlgrenska University Hospital S-413 45 Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fredrik Bäckhed, Assoc prof</last_name>
    <role>Study Chair</role>
    <affiliation>The Wallenberg Laboratory, Bruna Stråket 16, Sahlgrenska University Hospital, S-413 45 Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Per-Anders E Jansson, Adj prof</last_name>
    <phone>46 31 342 10 00</phone>
    <phone_ext>73 26</phone_ext>
    <email>per-anders.jansson@medic.gu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gothia Forum, CTC, Gröna Stråket 12, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>S-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaj Stenlöf, Director</last_name>
      <phone>46 708 76 01 30</phone>
      <email>kaj.stenlof@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Niklas Rydberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):979-84. Epub 2007 Jan 8.</citation>
    <PMID>17210919</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>June 14, 2012</last_update_submitted>
  <last_update_submitted_qc>June 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lactobacillus</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

